LDL particle size and lipid composition are risk factors for microalbuminuria in normotensive and normocholesterolemic patients with type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 66, Issue 3, 2004, Pages 229-236

  Matsui, Jun ^a   Tamasawa, Naoki ^a   Tanabe, Jutaro ^a   Kasai, Nobuhiko ^a   Murakami, Hiroshi ^a   Yamato, Kazumi ^a   Guan, Jingzhi ^a   Suda, Toshihiro ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Tocopherol; Microalbuminuria; Oxidation; Small dense LDL; Type 2 diabetes mellitus

Indexed keywords

ALBUMIN; ALPHA TOCOPHEROL; C PEPTIDE; COPPER SULFATE; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; THIOBARBITURIC ACID;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; DIET THERAPY; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIPID COMPOSITION; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATION; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEINURIA; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; UNIVERSITY HOSPITAL; URINARY EXCRETION;

AGED; ALBUMINURIA; ALPHA-TOCOPHEROL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERINSULINISM; HYPERTRIGLYCERIDEMIA; LIPIDS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PARTICLE SIZE; RISK FACTORS;

EID: 7944230759     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2004.03.011     Document Type: Article

References (49)

1. Andersen A.R., Christiansen J.S., Andersen J.K., Kreiner S., Deckert T. Diabetic nephropathy type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia. 25:1983;496-501
2. Pedrinelli R., Dell'Omo G., Di Bello V., Pontremoli R., Mariani M. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J. Hum. Hypertens. 16:2002;79-89
3. Campese V.M., Bianchi S., Bigazzi R. Association between hyperlipidemia and microalbuminuria in essential hypertension. Kidney Int. 71(Suppl.):1999;S10- 13
4. J.S. Yudkin, R.D. Forrester, C.A. Jackson, Microalbuminuria as predictor of vascular disease in non-diabetic subjects, Islington Diabetes Survey, Lancet II (1988) 530-533.
5. Kuusisto J., Mykkänen L., Pyörälä K., Laakso M. Hyperinsulinemic microalbuminuria: a new risk indicator for coronary heart disease. Circulation. 91:1995;831-837
6. Savage S., Jeffers B., Estacio R.O., Schrier R.W. Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care. 19:1996;1243-1248
7. Singh B.K., Mehta J.L. Management of dyslipidemia in the primary prevention heart disease. Curr. Opin. Cardiol. 17:2002;503-511
8. Matsuzaki M., Kita T., Mabuchi H., Matsuzawa Y., Nakaya N., Oikawa S., et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia - primary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ. J. 66:2002;1087-1095
9. Stewart M.W., Laker M.F., Dyer R.G., Game F., Mitcheson J., Winocour P.H., et al. Lipoprotein compositional abnormalities and insulin resistance in type II diabetic patients with mild hyperlipidemia. Arterioscler. Thromb. 13:1992;1046-1052
10. Campos H., Genest J.J., Blijilevens E., McNamara J.R., Jenner J.L., Ordovas J.M., et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler. Thromb. 12:1992;187-195
11. Dlahdenpera S.L., Syvänne M., Kahri J., Taskinen M.R. Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglyceride. Diabetologia. 39:1996;453-461
12. Steinberg U.P., Zhang H., Lougheed M. Role of oxidatively modified LDL in atherosclerosis. Free Radic. Biol. Med. 9:1990;155-168
13. de Graaf J., Hak-Lemmers H.L.M., Hectors M.P.C., Demacker P.N.M., Hendriks J.C.M., Stalenhoef A.F.H. Enhanced susceptibility to in vitro oxidation of dense low density lipoprotein subfraction in healthy subjects. Arterioscler. Thromb. 11:1991;298-306
14. Esterbauer H., Dieber-Rotheneder M., Sriegel G., Waeg G. Role of Vitamin E in preventing the oxidation of low-density lipoprotein. Am. J. Clin. Nutr. 53:1991;314S-321S
15. Reaven P.D., Barnett J., Herold D.A., Edelman S. Effects of Vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to oxidation and on protein glycation in NIDDM. Diabetes Care. 18:1995;807-816
16. Matsuo M., Matsumoto S., Iitaka Y., Niki E. Radical scavenging reactions of Vitamin E and its model compound in a tert-butylperoxyl radical generating system. J. Am. Chem. Soc. 111:1990;7179-7185
17. Abe K., Katsui G. Fluoremetric determination of tocopherol in serum. Jpn. Soc. Food Nutr. 28:1975;277-280
18. Hoefner D.M., Hodel S.D., O'Brien J.F., Branum E.L., Sun D., Meissner I., et al. Development of a rapid, quantitative method for LDL subfraction with use of the Quatimetrix Lipoprint LDL System. Clin. Chem. 47:2001;266-274
19. Yoshino G., Hirano T., Kazumi T. Treatment to small dense LDL. J. Atheroscler. Thromb. 9:2002;266-275
20. Yokode M., Kita T., Kikawa Y., Ogorochi T., Narumiya S., Kawai C. Stimulated arachidonate metabolism during foam cell transform of mouse peritoneal macrophages with oxidized low density lipoprotein. J. Clin. Invest. 81:1988;720-729
21. Fukuda M. Classification and treatment of diabetic retinopathy. Diabetes Res. Clin. Pract. 24(Suppl.):1944;S171-S176
22. Diabetic Retinopathy Study Research Group: Report 7, A modification of the Airlie House classification of diabetic retinopathy, Invest. Ophthalmol. Vis. Sci. 21 (1981) 210-226.
23. Consensus Panel: Report and recommendations of the San Antonio Conference on Diabetic Neuropathy, Ann. Neurol. 24 (1988) 99-106.
24. Temelkova-Kurktschiev T.S., Koehler C., Leonhardt W., Schaper F., Henkel E., Siegert G., et al. Increased intima-medial thickness in newly detected type 2 diabetes: risk factors. Diabetes Care. 22:1999;333-338
25. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia. 32:1989;219-226
26. Mattock M.B., Barnes D.J., Viberti G.C., Keen H., Burt D., Hughes J.M., et al. Microalbuminuria and coronary heart disease in NIDDM - an Incidence Study. Diabetes. 47:1998;1786-1792
27. Hirano T., Naito H., Kurokawa M., Ebara T., Nagano S., Adachi M., et al. High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy. Atherosclerosis. 123:1996;57-72
28. Fontbonne A., Eschwege E., Cambien F., Richard J.L., Ducimetiere P., Thibult N., et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia. 32:1989;300-304
29. Siegel R.D., Cupples A., Schaefer E.J., Wilson P.W. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism. 45:1996;1267-1272
30. Rowley K.G., Iser D.M., Best J.D., O'Dea K., Leonard D., McDermott R. Albuminuria in Australian aboriginal people: prevalence and associations with components of the metabolic syndrome. Diabetologia. 43:2000;1397-1403
31. Yla-Herttuala S., Palinski W., Rosenfeld M.E., Parthasarathy S., Crew T.E., Witztum J., et al. Evidence for the presence of oxidatively modified LDL in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84:1989;1086-1095
32. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:1999;115-126
33. Haffner S.M., Agil A., Mykkanen L., Stern M.P., Jialal I. Plasma oxidizability in subjects with normal glucose tolerance, impaired glucose tolerance, and NIDDM. Diabetes Care. 18:1995;646-653
34. Dimitriadis E., Griffin M., Owens D., Johnson A., Collins P., Tomkin G.H. Oxidation of low-density lipoprotein in NIDDM: its relationship to fatty acid composition. Diabetologia. 38:1995;1300-1306
35. Altamore E., Vendemaille G., Chicco D., Procacci V., Cirelli F. Increased lipid peroxides to macrovascular disease in type 2 diabetes. Diabetic Med. 8:1992;752-758
36. Mooradian A.D. Increased serum conjugated dienes in elderly diabetic patients. J. Am. Geriatr. Soc. 39:1991;571-574
37. Barakat H.A., Carpenter J.W., McLendon V.D., Khazanie P., Leggett N., Heath J., et al. Influence of obesity, impaired glucose tolerance, and NIDDM on LDL structure and composition - possible link between hyperinsulinemia and atherosclerosis. Diabetes. 39:1990;1527-1533
38. Feingold K.F., Grunfeld C., Pang M., Doerrler W., Krauss R. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler. Thromb. 12:1992;1496-1502
39. Isomaa B., Henricsson M., Almgren P., Tuomi T., Taskinen M.R., Groop L. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia. 44:2001;1148-1154
40. Sevanian A., Hwang J., Hodis H., Cazzolato G., Avogaro P., Bittolo-Bon G. Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscler. Thromb. Vasc. Biol. 16:1996;784-793
41. Glavind J., Hartmann S., Clemmesen J., Jessen K.E., Dam H. Studies on the role of lipoperoxides in human pathology. Acta Pathol. Microbiol. Scand. 30:1952;1-6
42. Carew T.E., Schwenke D.C., Steinberg D. Antiatherogenic effect of probucol unrelated to its hypercholesterolemic effects: evidence that antioxidants in vivo can selectively inhibits low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit. Proc. Natl. Sci. U.S.A. 84:1987;7725-7729
43. Gey K., Puska P. Plasma Vitamin E and A inversely related to mortality from ishemic heart disease in cross-cultural epidemiology. In Vitamin E: biochemistry and health implications. Ann. N. Y. Acad. Sci. 570:1989;262-282
44. Dieber-Rotheneders M., Puhl H., Waeg G., Striegl G., Esterbauer H. Effects of oral supplementation with D-α-tocopherol on the Vitamin E content of human low density lipoproteins and resistance to oxidation. J. Lipid Res. 32:1991;1325-1332
45. Ceriello A., Giugliano D., Quatrao A., Donzella C., Lefebvre P.J. Vitamin E reduction of protein glycosylation in diabetes. Diabetes Care. 14:1991;68-72
46. Wolff S.P., Dean R.T. Glucose autoxidation and protein modification: the potential role of autoxidative glycosylation in diabetes. Biochem. J. 23:1987;4243-4250
47. McNamara J.R., Small D.M., Li Z., Schaefer E.J. Differences in LDL subspecies involve alterations in lipid composition and conformational changes in apolipoprotein B. J. Lipid Res. 37:1996;1924-1935
48. Tribble D.L., Holl L.G., Wood P.D., Krauss R.M. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis. 93:1992;189-199
49. Kikuchi T., Onuma T., Tsutsui M., Boku A., Shimura M., Matsui J., et al. The effects of α-tocopherol on oxidation of low density lipoprotein in diabetic patients. Hirosaki Med. J. 46:1994;98-104